Literature DB >> 22319198

Complement activation in acetaminophen-induced liver injury in mice.

Rohit Singhal1, Patricia E Ganey, Robert A Roth.   

Abstract

Overdose with acetaminophen (APAP) results in acute liver failure in humans and experimental animals. Complement comprises more than 30 proteins that can participate in tissue injury and/or repair, but the role of complement activation in APAP-induced hepatotoxicity has not been evaluated. Treatment of male, C57BL6J mice with APAP (200-400 mg/kg) resulted in liver injury as evidenced by increased activity of alanine aminotransferase (ALT) in plasma and hepatocellular necrosis. Plasma concentration of the complement component C3 was significantly reduced 6 h after treatment with APAP, indicating complement activation, and C3b (detected by immunostaining) accumulated in the centrilobular areas of liver lobules. Pretreatment with cobra venom factor (CVF; 15 U/mouse) to deplete complement components abolished APAP-mediated C3b accumulation, and this was accompanied by reductions in plasma ALT activity, hepatocellular necrosis, hepatic neutrophil accumulation, and expression of inflammatory genes (interleukin-6, interleukin-10, and plasminogen activation inhibitor-1) at 24 h after APAP treatment. Loss of hepatocellular GSH was similar in APAP-treated mice pretreated with either saline or CVF, suggesting that CVF pretreatment did not affect APAP bioactivation. Mice with a genetic deficiency in C3 had reduced ALT activity 6 and 12 h after APAP administration compared with wild-type animals. These results reveal a key role for complement activation in hepatic inflammation and progression of injury during the pathogenesis of APAP-induced hepatotoxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22319198      PMCID: PMC3336815          DOI: 10.1124/jpet.111.189837

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  48 in total

Review 1.  Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next?

Authors:  Neil Kaplowitz
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

2.  Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays.

Authors:  Dimitrios Mastellos; József Prechl; Glória László; Krisztián Papp; Eszter Oláh; Emelia Argyropoulos; Silvia Franchini; Ruxandra Tudoran; Maciej Markiewski; John D Lambris; Anna Erdei
Journal:  Mol Immunol       Date:  2004-03       Impact factor: 4.407

3.  Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.

Authors:  M Clapperton; N Rolando; L Sandoval; E Davies; R Williams
Journal:  Eur J Clin Invest       Date:  1997-02       Impact factor: 4.686

4.  Role of proinflammatory cytokines in acetaminophen hepatotoxicity.

Authors:  M E Blazka; J L Wilmer; S D Holladay; R E Wilson; M I Luster
Journal:  Toxicol Appl Pharmacol       Date:  1995-07       Impact factor: 4.219

5.  Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen.

Authors:  D L Laskin; C R Gardner; V F Price; D J Jollow
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

6.  C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury.

Authors:  Maciej M Markiewski; Dimitrios Mastellos; Ruxandra Tudoran; Robert A DeAngelis; Christoph W Strey; Silvia Franchini; Rick A Wetsel; Anna Erdei; John D Lambris
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

7.  Studies in vivo of cobra factor and murine C3.

Authors:  M B Pepys
Journal:  Immunology       Date:  1975-02       Impact factor: 7.397

8.  Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement).

Authors:  C A Alper; D Balavitch
Journal:  Science       Date:  1976-03-26       Impact factor: 47.728

9.  Complement levels in patients with hepatic dysfunction.

Authors:  R T Ellison; C R Horsburgh; J Curd
Journal:  Dig Dis Sci       Date:  1990-02       Impact factor: 3.199

Review 10.  The dark side of C5a in sepsis.

Authors:  Peter A Ward
Journal:  Nat Rev Immunol       Date:  2004-02       Impact factor: 53.106

View more
  15 in total

1.  Liuweiwuling tablets attenuate acetaminophen-induced acute liver injury and promote liver regeneration in mice.

Authors:  Yan-Chang Lei; Wen Li; Pan Luo
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

2.  Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure.

Authors:  Tea L Laursen; Thomas D Sandahl; Sidsel Støy; Frank V Schiødt; William M Lee; Hendrik Vilstrup; Steffen Thiel; Henning Grønbaek
Journal:  Liver Int       Date:  2014-09-30       Impact factor: 5.828

3.  Benzyl alcohol protects against acetaminophen hepatotoxicity by inhibiting cytochrome P450 enzymes but causes mitochondrial dysfunction and cell death at higher doses.

Authors:  Kuo Du; Mitchell R McGill; Yuchao Xie; Hartmut Jaeschke
Journal:  Food Chem Toxicol       Date:  2015-10-30       Impact factor: 6.023

4.  Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy.

Authors:  Keely M Marshall; Songqing He; Zhi Zhong; Carl Atkinson; Stephen Tomlinson
Journal:  J Exp Med       Date:  2014-08-11       Impact factor: 14.307

5.  Hepatoprotective Effect of Silymarin (Silybum marianum) on Hepatotoxicity Induced by Acetaminophen in Spontaneously Hypertensive Rats.

Authors:  Abel Felipe Freitag; Gabriel Fernando Esteves Cardia; Bruno Ambrósio da Rocha; Rafael Pazzinatto Aguiar; Francielli Maria de Souza Silva-Comar; Ricardo Alexandre Spironello; Renata Grespan; Silvana Martins Caparroz-Assef; Ciomar Aparecida Bersani-Amado; Roberto Kenji Nakamura Cuman
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-02       Impact factor: 2.629

6.  C5a/C5aR pathway is essential for up-regulating SphK1 expression through p38-MAPK activation in acute liver failure.

Authors:  Yan-Chang Lei; Chun-Lei Lu; Ling Chen; Ke Ge; Ling-Ling Yang; Wen Li; Yuan-Hua Wu
Journal:  World J Gastroenterol       Date:  2016-12-14       Impact factor: 5.742

7.  Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions.

Authors:  Yuichi Miyashima; Yuichi Honma; Koichiro Miyagawa; Shinji Oe; Michio Senju; Michihiko Shibata; Masaaki Hiura; Shintaro Abe; Masaru Harada
Journal:  Intern Med       Date:  2016-12-15       Impact factor: 1.271

8.  Meta-Analysis of Large-Scale Toxicogenomic Data Finds Neuronal Regeneration Related Protein and Cathepsin D to Be Novel Biomarkers of Drug-Induced Toxicity.

Authors:  Hyosil Kim; Ju-Hwa Kim; So Youn Kim; Deokyeon Jo; Ho Jun Park; Jihyun Kim; Sungwon Jung; Hyun Seok Kim; KiYoung Lee
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

9.  High-Mobility Group Box 1-Induced Complement Activation Causes Sterile Inflammation.

Authors:  Sook Young Kim; Myoungsun Son; Sang Eun Lee; In Ho Park; Man Sup Kwak; Myeonggil Han; Hyun Sook Lee; Eun Sook Kim; Jae-Young Kim; Jong Eun Lee; Ji Eun Choi; Betty Diamond; Jeon-Soo Shin
Journal:  Front Immunol       Date:  2018-04-11       Impact factor: 7.561

10.  Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease.

Authors:  Joost Willebrords; Michaël Maes; Isabel Veloso Alves Pereira; Tereza Cristina da Silva; Veronica Mollica Govoni; Valéria Veras Lopes; Sara Crespo Yanguas; Valery I Shestopalov; Marina Sayuri Nogueira; Inar Alves de Castro; Anwar Farhood; Inge Mannaerts; Leo van Grunsven; Jephte Akakpo; Margitta Lebofsky; Hartmut Jaeschke; Bruno Cogliati; Mathieu Vinken
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-12-12       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.